Skip to main content
. 2020 Jan 6;11(1):8. doi: 10.1038/s41419-019-2203-z

Fig. 1. BCL-XL inhibition sensitizes human HSPCs to certain cytotoxic drugs.

Fig. 1

a, b Human CD34+ cells were transfected with lentiviral vectors targeting Luciferase (shLuci) or human BCL-XL (shBCL-XL). Knockdown efficiency of shBCL-XL was determined by qRT-PCR; mRNA expression was normalized to 18S. Bars represent mean ± SEM; n = 4 from four independent experiments; p = 0.0286 (a). In addition, protein levels were determined in CD34+GFP+ cells (b). c Apoptosis was determined in lentivirally transduced cells 24 h after end of viral transduction. d Lentivirally transduced CD34+ cells were subjected to cytotoxic treatment for 24 h; Control (Co, with serum), Serum deprivation (Serum depr.), 0.5 µg/ml VP16 (Etoposide), 0.05 µg/ml Taxol, 1 µg/ml Tunicamycin (Tu), 1 µM Staurosporine (Stau), 5 µM ABT-737. Cells were stained with Annexin V and 7-AAD and GFP+ cells were analyzed for percentage specific apoptosis by flow cytometry. Bars represent mean ± SEM, n = 4 from two independent experiments. The Mann–Whitney test was performed; p = 0.0286 for Tu and Stau.